Table 2 Treatment and dosimetric characteristics
From: Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases
Characteristic | No. patients (%) | Characteristic | No. patients (%) |
|---|---|---|---|
Prior thoracic surgery | Prescription dose (Gy) | ||
Yes | 12 (60) | 35 | 8 (40) |
No | 8 (40) | 40 | 12 (60) |
Prior chemotherapy | Max point dose (Gy) | ||
Yes | 15 (75) | Mean | 48.3 |
No | 5 (25) | Median | 46.7 |
PTV volume (cc) | Range | 41.7–57.1 | |
Mean | 111.3 | Major bronchus max dose (Gy) | |
Median | 85.8 | Mean | 46.7 |
Range | 22.6–300.0 | Median | 46.4 |
Conformality index | Range | 40.0–50.0 | |
Mean | 1.53 | Esophagus max dose (Gy) | |
Median | 1.50 | Mean | 28.7 |
Range | 1.21–1.93 | Median | 31.1 |
Rx isodose line (%) | Range | 10.8–40.6 | |
Mean | 75.5 | Spinal cord max dose (Gy) | |
Median | 75.2 | Mean | 12.7 |
Range | 70.0–80.0 | Median | 13.7 |
PTV coverage (%) | Range | 3.2–19.3 | |
Mean | 98.0 | Left ventricle max dose (Gy) | |
Median | 98.0 | Mean | 14.9 |
Range | 96–100 | Range | 5.1–37.3 |
Treatment length | Days | Total lung V15 Gy (cc) | |
Median | 7 | Mean | 399.4 |
Range | 5–8 | Range | 145.0–1005.0 |